FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters

16th September 2025 Uncategorised 0

After the FDA announced it was cracking down on what it has determined to be “misleading” or “deceptive” direct-to-consumer pharmaceutical ads, the floodgates have opened.

More: FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters
Source: fierce